NHS Faces Challenges in Patient Pathway Activation for Innovative Treatments
The NHS is encountering challenges in transitioning from the approval of innovative medical treatments to their real-world adoption. According to experts, the gap between approval and actual patient access is significant, with many treatments stalling due to system complexities. Arlene Neville from IQVIA highlights that organizations often assume clinical efficacy will naturally lead to adoption, but they face a complex system involving multiple sectors. The process of patient pathway activation requires understanding and redesigning these pathways to ensure system readiness for new treatments. This involves addressing bottlenecks, decision-making ownership, and operational constraints. 
